Sunday, June 1, 2003 | Oncolink

Oncolink Features

Find My Cancer Drug

A randomized study of concomitant radiotherapy with cisplatin or carboplatin versus radiotherapy alone in patients with locally advanced non-nasopharygeal head and neck cancer. A Hellenic Cooperative Oncology Group (HeCOG) phase III study Presenter: G FountzilasPresenter's Affiliation: Hellenic Cooperative Oncology GroupType of Session: ScientificBackground The prognosis of locally advanced head and neck cancer (HNC) is poor. More than 50% of patients with locally advanced HNC will...
Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluoruracil, leucovorin) as first-line therapy in subjects with metastatic CRC Presenter: H HurwitzPresenter's Affiliation: Duke UniversityType of Session: ScientificBackground Vascular endothelial growth factor (VEGF) is frequently overexpressed in cancers and plays an important role in tumor angiogenesis. Bevacizumab (BV)is...
Bladder preservation with induction chemotherapy (carboplatin/paclitaxel) followed by radiotherapy with concurrent paclitaxel. A study of the Hellenic Cooperative Oncology Group Presenter: G. AravantinosPresenter's Affiliation: Hellenic Cooperative Oncology GroupType of Session: PosterBackground Radical cystectomy remains the standard of care treatment for invasive bladder cancer. Comparable results have been obtained with...
Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Presenter: D CunninghamPresenter's Affiliation: BOND InvestigatorsType of Session: ScientificBackground Cetuximab is a chimeric anti-EGFR monoclonal antibody that results in the blockade of EGF and TGF-alpha. The downstream results of this blockade...
Docetaxel and carboplatin once every 3 weeks versus weekly docetaxel in advanced non-small cell lung cancer. Interim analysis of a multicenter phase III trial Presenter: H. GroenPresenter's Affiliation: Dutch Chest Physicians AssociationType of Session: ScientificBackground Taxane-based chemotherapy has been shown to have a modest response rate of 10-30% in advanced non-small cell lung cancer (NSCLC). ...
Early Study Results Promising: Oral Medication Active Against Skin Cancer Abramson Cancer Center Research Presented at ASCO: Abstract #2854 FOR IMMEDIATE RELEASE (Saturday, May 31, 2003, Chicago, IL) - Researchers from the Abramson Cancer Center of the University of Pennsylvania today presented early study results...
Early Study Results Promising: Oral Medication Active Against Skin Cancer Abramson Cancer Center Research Presented at ASCO: Abstract #2854 FOR IMMEDIATE RELEASE (Saturday, May 31, 2003, Chicago, IL) - Researchers from the Abramson Cancer Center of the University of Pennsylvania today presented early study results...
Induction chemotherapy followed by standard thoracic radiotherapy (Std. TRT) vs. hyperfractionated accelerated radiotherapy (HART) for patients with unresectable stage IIIA and B non-small cell lung cancer (NSCLC): Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597) Presenter: C.P. BelaniPresenter's Affiliation: ECOGType of Session: ScientificBackground The current standard of care for patients with locally advanced NSCLC is combined modality chemotherapy and thoracic irradiation. What has not been clearly...
Induction chemotherapy following simultaneous radio/chemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (Stage IIIA/IIIB) Presenter: R. M. HuberPresenter's Affiliation: University of Munich, Germany; BROCAT-GroupType of Session: ScientificBackground Studies of inoperable NSCLC patients have previously shown a small but statistically significant advantage in median...
Intergroup 0144 - phase III trial of 5-FU based chemotherapy regimens plus radiotherapy (XRT) in postoperative adjuvant rectal cancer. Bolus 5-FU vs prolonged venous infusion (PVI) before and after XRT + PVI vs bolus 5-FU + leukovorin (LV) + levamisole (LEV) before and after XRT + bolus 5-FU + LV Presenter: S.R. SmalleyPresenter's Affiliation: SWOGType of Session: ScientificBackground 5-FU based chemoradiotherapy is standard post-operative management of T3-4N0 or node positive rectal cancer patients. Controversy regarding the optimal method...
Isolated CNS relapse of acute lymphoblastic leukemia (ALL) treated with intensive systemic chemotherapy and delayed CNS radiation: A Pediatric Oncology Group Study Presenter: J.C. BarredoPresenter's Affiliation: Medical University of South CarolinaType of Session: ScientificBackground Event-free survival for patients suffering isolated CNS relapse of ALL after initial therapy has improved. The previous POG...
Late cardiotoxicity of mediastinal irradiation Presenter: JM AdamsPresenter's Affiliation: University of RochesterType of Session: ScientificBackground Most patients with childhood Hodgkin's Disease (HD) survive long-tem and many are treated with mediastinal irradiation (RT). Mediastinal RT is...
Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III nscls: RTOG 94-10 Presenter: W.J. CurranPresenter's Affiliation: RTOGType of Session: ScientificBackground There has been a demonstrated survival benefit of chemoradiation over radiation alone in stage III non-small cell lung cancer (NSCLC) This survival benefit has...
Neoadjuvant chemotherapy for primary high grade extremity soft tissue sarcoma: A matched case control study Presenter: S. R. GrobmyerPresenter's Affiliation: Memorial Sloan-Kettering Cancer Center and Dana-Farber Cancer InstituteType of Session: ScientificBackground The investigation of high grade (HG) extremity soft tissue sarcomas (STS) is often...
OncoLink TV: Special Live Webcast from ASCO 2003 ...
Phase II clinical experience with the proteasome inhibitor bortezomib (formerly PS-341) in patients with indolent lymphomas. Presenter: Owen A. O'ConnorPresenter's Affiliation: Memorial Sloan Kettering Cancer CenterType of Session: ScientificBackground The ubiquitin proteasome pathway plays an essential role in the degradation of most intracellular proteins in eukaryotic...
Phase II study of oblimersen sodium (G3139) alone and with R-CHOP in mantle cell lymphoma Presenter: J.P. LeonardPresenter's Affiliation: Weill Medical College of Cornell UniversityType of Session: ScientificBackground Bcl-2 overexpression is involved in inhibition of apoptosis and therefore results in tumor cell growth. Bcl-2 is highly...
Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Initial results from intergroup trial 0139 (RTOG 93-09) Presenter: K.S. AlbainPresenter's Affiliation: RTOGType of Session: Scientific Background Patients with Stage IIIA NSCLC have a poor prognosis, though chemoradiation (CRT) remains the standard of care for pathologic N2 disease. Many have...
Phase III dose-randomization study of imatinib mesylate (STI571, Gleevac) for GIST: Intergroup S0003 early results Presenter: RS BenjaminPresenter's Affiliation: Sarcoma IntergroupType of Session: ScientificBackground Imatinib has been shown to have high rates of activity in most gastro-intestinal stromal tumors (GIST) due to its specific activity against the KIT...
Radiation Therapy Oncology Group (RTOG) 9514: A phase II study of neoadjuvant chemotherapy (CT) and radiation therapy (RT) in the management of high risk (HR), high grade (HG) soft tissue sarcomas (STS) of the extremities and body wall Presenter: W. G. KraybillPresenter's Affiliation: RTOGType of Session: ScientificBackground The preliminary data from this RTOG phase II trial of neoadjuvant chemotherapy and radiation in high risk soft tissue sarcoma patients was first presented at...
Subsequent neoplasms (SNs) of the central nervous system (CNS) in survivors of childhood cancer: a case/control study from the Children's Cancer Survivor Study (CCSS) Presenter: J.P. NegliaPresenter's Affiliation: University of MinnesotaType of Session: ScientificBackground Childhood cancer patients survivors are known to be at increased risk of subsequent CNS malignancies. An association between subsequent...
Ten-Year outcomes for elderly women treated with breast-conserving surgery and definitive breast irradiation for early stage breast cancer. Presenter: Sandra L. UrtishakPresenter's Affiliation: Hospital of the University of PennsylvaniaType of Session: PosterBackground Breast cancer is a major cause of morbidity and mortality among elderly women, but it is not well studied in this...
The impact of concurrent versus sequential tamoxifen and radiation therapy in breast cancer patients undergoing breast conservation therapy. Presenter: Vasathi J. ChristnesenPresenter's Affiliation: Hospital of the University of PennsylvaniaType of Session: PosterBackground Hormonal Therapy plays an important role in the adjuvant therapy of breast cancer patients. The optimal sequencing...
The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer (MBC) in a population based cohort. Presenter: S.K.L.ChiaPresenter's Affiliation: British Columbia Cancer AgencyType of Session: ScientificBackground Metastatic Breast Cancer is an extremely prevalent diagnosis. Median OS for these patients has historically been 12-24 months. No...